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New Take-Home Screening Tests for Colon Cancer 
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Background 
Colorectal cancer is the second-leading cause 
of cancer-related deaths in the United States and 
the third most frequently diagnosed cancer in the 
U.S. and Canada.1-3  Both men and women are at 
risk for colon cancer.  It is more common in those 
who are 50 years of age or older; risk increases 
with age.  Those with a family history of 
colorectal cancer or colorectal polyps are also at 
increased risk for developing colorectal cancer. 1-3  
The U.S. Preventative Services Task Force 
(USPSTF) recommends that initial screening be 
performed for all men and women who are 50 
years of age or older and who are at average risk 
for colorectal cancer.  They classify this 
recommendation as grade “A” based on clinical 
evidence from well-designed, well-conducted 
studies demonstrating that screening improves 
health outcomes where benefits substantially 
outweigh harms.  Those who are higher risk 
should have initial screening at an earlier age.4   
The USPSTF screening options for colorectal 
cancer include: home fecal occult blood testing 
(FOBT), flexible sigmoidoscopy, the combination 
of home FOBT and flexible sigmoidoscopy, 
colonoscopy, and double-contrast barium enema.  
Traditional FOBT products using a fecal guaiac 
smear test include Hemoccult, Seracult, and 
Coloscreen.   
The Task Force states that the choice of 
screening method should be based on the patient 
preferences, medical contraindications, patient 
adherence, and available testing resources and 
follow-up.  They further state that “there are 
insufficient data to determine which screening 
strategy is best in terms of the balance of benefits 
and potential harms or cost-effectiveness.  It is 
unclear whether the increased accuracy of 
colonoscopy compared with alternative screening 
methods offsets the procedure’s additional 
complications, inconvenience, and costs.”4 
Testing intervals vary with the specific 
screening method.  Annual FOBT, ten year 
intervals for colonoscopy, five year intervals for 
flexible sigmoidoscopy or double-contrast barium 
enemas are usual recommendations for average-
risk patients.  Average risk patients include: those 
without inflammatory bowel disease or autosomal 
inherited colorectal cancers, and those without a 
family history for colorectal neoplasia.3,4  With 
increased risk for colorectal cancer, screening 
intervals shorten.  Whenever a positive screening 
test occurs, a follow-up colonoscopy is 
recommended.3,4 
Colorectal screening recommendations of the 
National Comprehensive Cancer Network, the 
American Cancer Society, the American College 
of Surgeons, the American College of 
Obstetricians and Gynecologists, and the 
American Academy of Family Physicians are all 
similar to those of the USPSTF.3,4   
Screening guidelines from the Canadian 
Association of Gastroenterology and the Canadian 
Digestive Health Foundation recommend biennial 
FOBT using guaiac-based or immunochemical 
testing.  They also recommend flexible 
sigmoidoscopy every five years, flexible 
sigmoidoscopy combined with FOBT every five 
years, double contrast barium enema every five 
years, or colonoscopy every ten years for those 
individuals at average risk.2 
Newer screening technologies for colorectal 
cancer include CT colonography (virtual 
colonoscopy), immunochemical fecal occult blood 
tests (iFOBT or FIT), stool screening using 
molecular markers, and capsule video endoscopy.5  
The American Cancer Society’s (ACS) Colorectal 
Cancer Advisory Group has recommended only 
iFOBT as an accepted screening method.  In 2002, 
the ACS added iFOBT to their recommendation 
list as an annual alternative to FOBT.6 
The USPSTF does not recommend digital 
rectal exam or use of a single office FOBT using a 
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stool sample obtained by digital rectal exam.7  
Collins, et al in a recent prospective cohort study 
concluded that single digital FOBT is a poor 
screening method and cannot be recommended as 
a single test.  Only 4.6% of patients with 
advanced proximal neoplasia had positive results 
with a single digital FOBT test.  They conclude 
that if a patient is screened using this single 
office-based method and results are negative, the 
patient should be further screened with at-home 
six-sample FOBT testing or another screening 
method [Evidence level B; clinical cohort study].8 
 
Screening Test Accuracy, Detection Ability, 
and Reliability 
The USPSTF Clinical Guidelines provide an 
evidence-based summary of colorectal cancer 
screening characteristics.7,9 
FOBT – The sensitivity of FOBT varies with 
the testing procedure depending on use of a 
hydrated or dehydrated specimen.  Sensitivity of a 
single test is estimated at approximately 40% but 
increases to between 50% and 60% if the 
specimen is rehydrated.  Rehydration refers to the 
addition of distilled water to the sample just 
before slide development.  Single test specificity 
is estimated at 96% to 98%.  Rehydration of the 
specimen reduces specificity to approximately 
90%.7  Sensitivity refers to the ability of the test to 
produce a positive result in a patient with 
colorectal cancer.  Specificity relates the 
probability that the test will produce a negative 
result in a patient who does not have colorectal 
cancer.   
Guaiac-based FOBTs have been thought to 
produce false-positive results when patients have 
ingested red meat, fresh fruits, or vegetables.  
Heme contained in red meat and peroxidases 
contained in fruits and vegetables can cause these 
false results.9,10  Fresh stool specimens do not 
allow degradation of vegetable peroxidases which 
can sometimes cause false-positive results.9  A 
meta-analysis of five randomized trials found that 
positivity rates do not seem to be affected by 
dietary restrictions where unrehydrated, guaiac-
based FOBTs were used [Evidence level A; high-
quality meta-analysis (quantitative systematic 
review)].25 
Chronic aspirin or non steroidal anti-
inflammatory agents (NSAIDs) have been thought 
to produce false-positives.11  In a study by Kahi et 
al, the authors concluded that aspirin and NSAID 
use is not a risk factor for false-positive FOBTs 
[Evidence level B; clinical cohort study].12  
Ingestion of ascorbic acid can cause false-
negatives due to inhibition of the guaiac 
reaction.10 
Sigmoidoscopy – Single screening 
sigmoidoscopy detects 68% to 78% of advanced 
neoplasia.9  Approximately seven cancers and 60 
large or high-risk polyps are detected per 1,000 
examinations.7  Sigmoidoscopy visualizes only 
the lower half of the colon.7 
FOBT and Sigmoidoscopy – One-time 
screening detects 76% of advanced neoplasia.  
The combination of these two methods may 
increase detection yields.9 
Double-contrast Barium Enema – One-time 
screening sensitivity for cancer or large polyps is 
approximately 48% with a range of 24% to 67%.9 
Colonoscopy – The sensitivity for large 
adenomas is 90% and is probably higher for 
cancer.9  The estimated sensitivity for small 
polyps (< one centimeter) is 75%.7,9 
 
Immunochemical Fecal Occult Blood Tests 
(iFOBT) 
In 2002, the American Cancer Society added 
iFOBT to their recommendation list as an annual 
alternative to FOBT.6   
In 2003, the Centers for Medicare and 
Medicaid Services CMS) issued a decision memo 
for screening immunoassay FOBT supporting 
iFOBT.  Their decision states that “the test 
appears to have modestly better test performance 
characteristics and patient compliance compared 
to existing methods for detecting fecal occult 
blood.”13 
IFOBT products include Hemoccult ICT 
available in the U.S. and Canada, as well as 
Hemosure One-Step, immoCARE, Instant-View 
FOBT, InSure, and MonoHaem in the U.S.5   
Immunochemical fecal occult blood tests use 
antibodies to detect the globin portion of human 
hemoglobin.  If hemoglobin is present, the test 
antibody attaches to its antigens producing a 
positive test result.  Because the test is specific for 
human hemoglobin, there are fewer false-positive 
tests.  Meats, fruits, vegetables, and as well as 
aspirin, NSAIDs, and ascorbic acid do not cause 
problems.  The tests are intended to detect lower 
gastrointestinal bleeding. 
In a study by Morikawa, et al, iFOBT 
sensitivity for advanced neoplasia was 27.1% and 
(Detail-Document #211007:  Page 3 of 5) 
More. . . 
Copyright © 2005 by Therapeutic Research Center 
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone:  209-472-2240 ~ Fax:  209-472-2249 
www.pharmacistsletter.com ~ www.prescribersletter.com  
65.8% for cancer.  Test specificity was 95.1% for 
advanced neoplasia and 94.6% for cancer.  The 
test product used in the study was Magstream 
1000/Hem SP which was a predecessor to 
HemeSelect, now Hemoccult ICT.14 
Greenberg, et al compared the sensitivities and 
specificities for Hemoccult II (FOBT) with 
HemeSelect (older predecessor of Hemoccult ICT) 
and FlexSure (later predecessor of Hemoccult 
ICT) [iFOBTs].15  The following table identifies 
these comparisons: 
 
 Hemoccult 
II 
HemeSelect FlexSure 
Sensitivity, 
cancer 
85.7% 83.3% 87.5% 
Specificity, 
cancer 
92.8% 88.2% 86.2% 
Sensitivity,  
adenoma > 
1 cm 
20.5% 37.1% 35.9% 
Specificity,  
adenoma > 
1 cm 
91.5% 88.3% 85.6% 
 
In general, iFOBT has a higher sensitivity for 
cancer but probably lower specificity compared 
with guaiac-based FOBT. 
Hemoccult ICT is supplied as a three card 
patient test kit.  Each card has two specimen 
collection zones.  Patients are instructed to place 
two different swabs of the collected stool on each 
collection zone.  Three kits are provided so that 
the patient will collect a stool sample on three 
consecutive days.  The test analytical sensitivity is 
approximately 300 mcg hemoglobin per gram of 
feces (mcg/Hb/g) compared with Hemoccult and 
Hemoccult II at approximately 750 mcg/Hb/g.26  
The suggested list price for a patient kit is $2.50.  
Each kit comes with a mailing envelope so that 
the specimens can be mailed or brought back to 
the health care professional’s office.16 
Hemosure One-Step kit contains a collection 
pad for capturing the stool specimen, a collection 
tube with a poke spiral applicator for insertion 
into six sites of the stool specimen, and a mailing 
envelope.  Analytical test sensitivity is 
approximately 50 mcg/Hb/g of stool.  Only one 
stool specimen is used.  The suggested list price 
for the kit $10.00.17 
The immoCARE product provides a stool 
specimen collection stick and bottle of buffer 
solution.  The patient places the stool-containing 
swab into the bottle of buffer solution.  Once 
received by a health care professional, the 
specimen-bottle is shaken, the tip of the bottle is 
broken and two drops are applied to a test 
cassette.  The results can be read in five minutes.  
A single stool sample is used.  The approximate 
analytical test sensitivity is 30 mcg/Hb/g of feces.  
The suggested list price for immoCARE is 
$15.40.18 
Instant-View FOBT II is available with a 
specimen collection tube, used as a sample 
applicator, and a cassette.  Using the applicator, 
the sample is placed on the cassette.  It provides a 
visual result in five to ten minutes upon addition 
of a stool swab sample.  Analytical test sensitivity 
is approximately 50 mcg/Hb/g of feces.  Only one 
stool specimen is used.  The suggested list price is 
$9.50 per test.19 
The InSure patient kit consists of a test card 
with a specimen sampling brush and a mailing 
envelope.  With InSure, the stool sample is 
collected by brushing the surface of the stool in 
the toilet bowl. The sample is then applied with 
the brush to the test card.  The process is repeated 
with a second sample.  The patient mails the 
completed test to Quest Diagnostics laboratory for 
processing.  The analytical test sensitivity is about 
50 mcg/Hb/g of feces.20 
MonoHaem uses a three card two specimen 
application per card process.  The patient kit 
contains cards, applicators, and a storage bag for 
return to the healthcare professional office.  
Approximate test sensitivity is 1,000 mcg/Hb/g to 
2,000 mcg/Hb/g of feces.  The suggested list price 
is $2.10 per kit.21  
All of the above iFOBT FDA approved 
products are Clinical Laboratory Improvement 
Amendments (CLIA) waived tests. 
Current Procedural Terminology (CPT-4) 
codes have been approved by CMS for Medicare 
billing of iFOBT.  They are G0328QW for testing 
as a cancer screen and 82274QW for any use 
other than as a cancer screen for CLIA waived 
iFOBT.  The reimbursement is $22.22.22,23 
 
Commentary 
These new immunochemical fecal occult blood 
tests generally provide a higher sensitivity for 
FOBT screening when compared with guaiac tests 
and equal convenience for patients using at-home 
testing.  Increased stool sampling frequency from 
a single collection to two or three consecutive day 
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sampling increases test sensitivity24 and may help 
identify intermittent bleeding.  Repeated sampling 
may however, decrease test compliance.  
Clinically, they eliminate some of the past 
concerns regarding false-positive or false-negative 
test results with guaiac-based FOBTs. 
Immunochemical FOBTs are generally not 
available for patient purchase at pharmacies; they 
are supplied to physician offices, laboratories, or 
clinics.  ImmoCARE is available under the name, 
ColonCARE, at some pharmacies for patient 
purchase.  ColonCARE is identical to immoCARE. 
Despite the method chosen for colorectal 
cancer screening, the most important aspect is 
patient completion of routine periodic testing by 
all average-risk men and women who are 50 years 
of age or older.  Those who are at a higher risk 
should undergo routine periodic screening at an 
earlier age. 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
clinical review article.  Am Fam Physician 2002;65:251-8. 
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